Reviva Pharmaceuticals Holdings, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
OQB
Reviva Pharmaceuticals Holdings, Inc. issued a supplement to its definitive proxy statement, correcting previously understated figures related to its proposed reverse stock split.
OQB
Reviva Pharmaceuticals Holdings, Inc. has filed a definitive proxy statement with the SEC.
OQB
Reviva Pharmaceuticals Holdings, Inc. calls its Annual Meeting to vote on a reverse stock split to maintain Nasdaq listing, an increase in authorized shares, and director elections.
OQB
DEF 14A: Reviva Pharmaceuticals Seeks Stockholder Approval for Share Increase at Upcoming Annual Meeting
Reviva Pharmaceuticals is holding its annual meeting on December 10, 2024, to vote on key proposals including increasing authorized shares and electing directors.